share_log

Heron Therapeutics Analyst Ratings

Benzinga ·  Jul 25, 2023 04:13
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/25/2023 224.68% Needham $6 → $5 Maintains Buy
05/12/2023 289.61% Needham $7 → $6 Maintains Buy
04/21/2023 354.55% Needham → $7 Reiterates → Buy
03/24/2023 549.35% Evercore ISI Group $15 → $10 Maintains Outperform
03/24/2023 354.55% Needham $8 → $7 Maintains Buy
11/09/2022 419.48% Needham $10 → $8 Maintains Buy
06/30/2022 549.35% Needham $14 → $10 Maintains Buy
05/10/2022 809.09% Needham $16 → $14 Maintains Buy
12/02/2020 1458.44% SVB Leerink $21 → $24 Maintains Outperform
05/27/2020 1458.44% Guggenheim → $24 Initiates Coverage On → Buy
03/02/2020 2757.14% Needham $48 → $44 Maintains Buy
02/20/2020 3016.88% Needham $50 → $48 Maintains Buy
10/03/2019 1977.92% JMP Securities $38 → $32 Reiterates → Market Outperform
09/14/2018 3471.43% Stifel → $55 Initiates Coverage On → Buy

What is the target price for Heron Therapeutics (HRTX)?

The latest price target for Heron Therapeutics (NASDAQ: HRTX) was reported by Needham on July 25, 2023. The analyst firm set a price target for $5.00 expecting HRTX to rise to within 12 months (a possible 224.68% upside). 6 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Heron Therapeutics (HRTX)?

The latest analyst rating for Heron Therapeutics (NASDAQ: HRTX) was provided by Needham, and Heron Therapeutics maintained their buy rating.

When is the next analyst rating going to be posted or updated for Heron Therapeutics (HRTX)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on July 25, 2023 so you should expect the next rating to be made available sometime around July 25, 2024.

Is the Analyst Rating Heron Therapeutics (HRTX) correct?

While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a maintained with a price target of $6.00 to $5.00. The current price Heron Therapeutics (HRTX) is trading at is $1.54, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment